Dark

QURE
uniQure N.V.
stock NASDAQ

At Close

Aug 15, 2025 3:59:56 PM EDT

16.19USD+2.630%(+0.41)1,360,994

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 15, 2025 9:27:30 AM EDT

16.20USD+2.662%(+0.42)6,845

After-hours

Aug 15, 2025 4:10:30 PM EDT

15.95USD-1.513%(-0.24)12,994

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

09:47AM EST Overview Of Value Stocks In The Healthcare Sector Benzinga

Dec 27, 2021

09:55AM EST 5 Value Stocks In The Healthcare Sector Benzinga

Dec 17, 2021

10:18AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 Benzinga

04:34AM EST Raymond James Downgrades uniQure to Outperform, Lowers Price Target to $58 Benzinga

Dec 16, 2021

02:31PM EST Mid-Afternoon Market Update: Nasdaq Down 2.5%; Calliditas Therapeutics Shares Spike Higher Benzinga

12:23PM EST Mid-Day Market Update: Gold Rises 2%; IronNet Shares Plummet Benzinga

10:49AM EST Shares of uniQure N.V. (QURE) are slipping over 23% on Thursday morning after the gene therapy company provided clinical update on first patients in phase I/II clinical trial of AMT-130 gene therapy for the treatment of Huntington's Disease. RTTNews

10:24AM EST Mid-Morning Market Update: Markets Mixed; Accenture Beats Q1 Estimates Benzinga

07:17AM EST uniQure Announces Clinical Update On First Patients In Phase I/II Clinical Trial Of AMT-130 Gene Therapy For The Treatment Of Huntington's Disease Benzinga

07:00AM EST uniQure Announces Clinical Update on First Patients in Phase I/II GlobeNewswire Inc

Dec 15, 2021

07:36AM EST CSL Behring Gets Accelerated CHMP Assessment For Etranacogene Dezaparvovec For Patients Living With Hemophilia B RTTNews

07:33AM EST CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec PR Newswire

Dec 9, 2021

09:45PM EST uniQure And CSL Behring Announce Primary Endpoint Achieved In HOPE-B Pivotal Trial Of Etranacogene Dezaparvovec Gene Therapy In Patients With Hemophilia B Benzinga

07:05AM EST ~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~ GlobeNewswire Inc

Nov 22, 2021

09:45AM EST A Look Into Healthcare Sector Value Stocks Benzinga

Nov 2, 2021

10:50AM EDT uniQure Announces Recommendation From Data Safety Monitoring Board In Phase I/II Clinical Trial Of AMT-130; No Significant Safety Concerns Observed In First Four Patients Enrolled In Higher-Dose Cohort, Enrollment Expected to be Completed By Mid-2022 Benzinga

07:05AM EDT ~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ GlobeNewswire Inc

Nov 1, 2021

07:05AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: GlobeNewswire Inc

Oct 27, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2021 Benzinga

08:42AM EDT William Blair Initiates Coverage On uniQure with Outperform Rating, Announces Price Target of $66 Benzinga

Oct 25, 2021

07:17AM EDT uniQure Q3 EPS $(0.79) Up From $(1.21) YoY, Sales $2.00M Up From $1.79M YoY Benzinga

07:05AM EDT ~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~~W0: GlobeNewswire Inc

Oct 21, 2021

09:30AM EDT uniQure Announces the Appointment of Rachelle GlobeNewswire Inc

Oct 19, 2021

07:15AM EDT uniQure Highlights Presentations At The Annual Meeting Of The European Society Of Gene And Cell Therapy Benzinga

07:05AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021. GlobeNewswire Inc

Sep 30, 2021

Sep 20, 2021

10:44AM EDT 5 Value Stocks In The Healthcare Sector Benzinga

Sep 7, 2021

06:25AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 6.10 A.M. EDT). RTTNews

Sep 3, 2021

06:56PM EDT Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join PR Newswire

Aug 30, 2021

07:09AM EDT uniQure Announces Completion Of Additional Patient Procedures Following Positive Recommendation From Data Safety Monitoring Board In Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease Benzinga

07:05AM EDT ~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ GlobeNewswire Inc

Jul 27, 2021

12:35PM EDT UPDATE: Credit Suisse On uniQure Price Target Raise Earlier: Firm Notes Sufficient Cash Position For Operations Into 1H24 At $677.3M; Focuses On AMT-061 Treatment Of HemB With BLA Submission Expected 1Q22, Sees AMT-130 For Huntington's On Track Benzinga

11:13AM EDT Credit Suisse Maintains Outperform on uniQure, Raises Price Target to $81 Benzinga

Jul 26, 2021

07:08AM EDT uniQure Q2 EPS $8.51 Up From $(0.96) YoY Benzinga

07:05AM EDT ~ Expanded gene therapy pipeline with four new research programs and announced acquisitionof Corlieve Therapeutics ~~W0: GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 2, 2021

09:00AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are oral presentations, will be delivered at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held July 17-21, 2021. GlobeNewswire Inc

Jun 24, 2021

11:20AM EDT UPDATE: Chardan Earlier Commented On uniQure Buy Rating: Firm Believes That A 1-Quarter Delay In EtranaDez Filing Could Result In A Better Label With Enhanced Durability Statements Benzinga

Jun 23, 2021

01:03PM EDT UPDATE: Chardan Earlier Commented On uniQure N.V. Buy Reiteration: EntranaDez BLA Expected To Be Submitted In Q1'22; Phase III HOPE-B Trial Shows Sustained Increases In Factor IX Activity. Benzinga

01:01PM EDT Chardan Reiterates Buy Rating On uniQure N.V. With $100 Price Target. Benzinga

Jun 22, 2021

02:50PM EDT One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels Benzinga

12:48PM EDT UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition Benzinga

11:40AM EDT uniQure Shares To Resume Trade At 11:50 a.m. EDT Benzinga

11:36AM EDT UPDATE: uniQure Says Will Now Conduct As Sole Primary Endpoint For Hemophilia B Candidate 'a non-inferiority analysis of annualized bleeding rates (ABR) at 78 weeks after the administration (approximately 52-weeks after steady-state is achieved)' Benzinga

11:35AM EDT UPDATE: uniQure Says Co. Held Pre-Biologics License Application Submission Meeting With FDA, Aligned On Primary Endpoint Analysis Benzinga

11:34AM EDT uniQure Reports 52-Week Clinical Data From HOPE-B Trial Of Hemophilia B Treatment Candidate: Showed 'Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following...' Benzinga

11:33AM EDT uniQure To Buy Corlieve Therapeutics For 46.3M Benzinga

11:32AM EDT ~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec~~W0: GlobeNewswire Inc

11:31AM EDT ~ Expands uniQures Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~ GlobeNewswire Inc

08:25AM EDT UniQure Shares Halted On Code News Pending Benzinga

Jun 16, 2021

07:07AM EDT uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease Benzinga

07:05AM EDT uniQure Announces Enrollment of First Two Patients in Second GlobeNewswire Inc

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

07:11AM EDT BTIG Initiates Coverage On uniQure with Buy Rating, Announces Price Target of $46 Benzinga

Jun 2, 2021

10:31AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: GlobeNewswire Inc

May 27, 2021

11:48AM EDT DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged Benzinga

07:32AM EDT UniQure Says Positive Recommendation To Advance Phase I/II Trial Of AMT-130 For Huntington's Disease RTTNews

07:07AM EDT uniQure Announces Positive Recommendation To Advance Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease Benzinga

07:05AM EDT uniQure Announces Positive Recommendation to Advance Phase I/II GlobeNewswire Inc

May 21, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 Benzinga

06:35AM EDT UBS Initiates Coverage On uniQure with Neutral Rating, Announces Price Target of $40 Benzinga

May 19, 2021

06:19AM EDT HC Wainwright & Co. Maintains Buy on uniQure, Raises Price Target to $90 Benzinga

May 13, 2021

07:13AM EDT uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector Benzinga

07:00AM EDT ~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~ GlobeNewswire Inc

May 10, 2021

07:10AM EDT uniQure Q1 EPS $(0.91) Down From $(0.63) YoY, Sales $454.00K Up From $104.00K YoY Benzinga

07:05AM EDT ~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~~W0: GlobeNewswire Inc

May 6, 2021

07:06AM EDT CSL Behring Announces Closing of Global Commercialization and License Agreement PR Newswire

07:00AM EDT uniQure announces closing of commercialization and license GlobeNewswire Inc

May 3, 2021

07:05AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: GlobeNewswire Inc

Apr 28, 2021

07:05AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which two are oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being held May 11-14. GlobeNewswire Inc

Apr 26, 2021

09:32AM EDT Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy Benzinga

08:34AM EDT UniQure's Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy Program Benzinga

07:08AM EDT uniQure Announces FDA Removes Clinical Hold On Hemophilia B Gene Therapy Program Benzinga

07:05AM EDT uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene GlobeNewswire Inc

Apr 8, 2021

07:08AM EDT uniQure Highlights Publications Of Preclinical Data For AMT-130 In Huntington's Disease Benzinga

07:05AM EDT uniQure Announces Publications of Preclinical Data for AMT-130 in GlobeNewswire Inc

Apr 5, 2021

07:09AM EDT uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease Benzinga

07:05AM EDT uniQure Announces Completion of Enrollment in First Cohort of GlobeNewswire Inc

Apr 1, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2021 Benzinga

07:05AM EDT uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: GlobeNewswire Inc

06:43AM EDT Mizuho Upgrades uniQure to Buy, Announces $52 Price Target Benzinga

Mar 29, 2021

09:34AM EDT Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient Benzinga

07:10AM EDT uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma in Hemophilia B Gene Therapy Program Benzinga

07:05AM EDT ~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the causeof HCC in HOPE-B pivotal trial ~~W0: GlobeNewswire Inc

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 2, 2021

08:00AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

05:03AM EST Chardan Capital Maintains Buy on uniQure, Raises Price Target to $100 Benzinga

Mar 1, 2021

07:23AM EST UniQure Reports FY20 EPS $(2.81) Up From $(3.11) YoY, Sales $37.514M Up From $7.281M YoY Benzinga

07:05AM EST ~ Six patient procedures now completed in Phase I/II for Huntingtons disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~~W0: GlobeNewswire Inc

Feb 26, 2021

07:05AM EST uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: GlobeNewswire Inc

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 9, 2021

01:47AM EST ATHE Gets Funded For Parkinson's Research, No Safety RTTNews

Feb 8, 2021

09:57AM EST No Safety Concerns Observed In Uniqure's Early-Stage Huntington's Gene Therapy Study, DSMB Says Benzinga

07:10AM EST UniQure Says its Data Safety Monitoring Board Did Not Note Safety Concerns to Prevent Dosing Benzinga

07:05AM EST uniQure Announces Positive Recommendation from Data Safety GlobeNewswire Inc

Feb 1, 2021

Dec 26, 2020

09:16AM EST The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks Benzinga

Dec 23, 2020

04:20AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Dec 21, 2020

02:51PM EST Mid-Afternoon Market Update: Dow Turns Positive; uniQure Shares Slide Benzinga

12:13PM EST Mid-Day Market Update: Crude Oil Down 4%; 500.com Shares Spike Higher Benzinga

10:22AM EST Mid-Morning Market Update: Markets Open Lower; FactSet Research Beats Q1 Estimates Benzinga

07:56AM EST UniQure Plunges As FDA Slaps Clinical Hold On Hemophilia B Gene Therapy Study On Possible Liver Cancer Link Benzinga

07:26AM EST uniQure's Hemophilia B Gene Therapy Program Placed on Clinical Hold by the FDA Benzinga

07:05AM EST uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program GlobeNewswire Inc

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

07:05AM EST uniQure Announces Data From the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B Met The First Primary Endpoint Benzinga

07:00AM EST ~ First primary endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~ GlobeNewswire Inc

Dec 7, 2020

04:05PM EST ~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ GlobeNewswire Inc

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 2, 2020

07:05AM EST uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences: GlobeNewswire Inc

Nov 30, 2020

07:05AM EST ~ Strong Presence at ASH FeaturingFive Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~~W0: GlobeNewswire Inc

Nov 20, 2020

09:56AM EST uniQure shares were trading higher after Credit Suisse maintained an Outperform rating on the stock and raised its price target from $76 to $78. Benzinga

08:33AM EST Credit Suisse Maintains Outperform on uniQure, Raises Price Target to $78 Benzinga

Nov 19, 2020

09:15AM EST uniQure Reports Top-Line Data From HOPE-B Pivotal Trial Of Etranacogen Dezaparvovec Gene Therapy In Patients With Hemophilia B Met Primary Endpoint Benzinga

09:10AM EST ~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~ GlobeNewswire Inc

Nov 11, 2020

10:58AM EST Berenberg Initiates Coverage On uniQure with Buy Rating, Announces Price Target of $59 Benzinga

Nov 4, 2020

10:47AM EST uniQure Highlights Clinical Data Presentations For American Society Of Hematology Dec. 6, 7 Benzinga

10:47AM EST uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation and three poster presentations, will be delivered at the 62nd American Society of Hematology (ASH) Annual Meeting, which will be held December 5-8 asa virtual event. GlobeNewswire Inc

07:40AM EST Cantor Fitzgerald Assumes uniQure at Overweight, Announces Price Target of $65 Benzinga

07:05AM EST uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire Inc

Oct 27, 2020

07:13AM EDT uniQure Q3 EPS $(1.21) Down From $(0.58) YoY, Sales $1.80M Up From $1.05M YoY Benzinga

07:05AM EDT ~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntingtons Disease ~ GlobeNewswire Inc

Oct 23, 2020

10:48AM EDT Benzinga's Top Upgrades, Downgrades For October 23, 2020 Benzinga

06:18AM EDT RBC Capital Initiates Coverage On uniQure with Outperform Rating, Announces Price Target of $61 Benzinga

Oct 13, 2020

07:13AM EDT UniQure Says Two Additional Patient Procedures Completed In Phase I/II Clinical Trial Of AMT-130 RTTNews

07:11AM EDT uniQure Announces Enrollment Of Next Two Patients In Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease Benzinga

07:05AM EDT uniQure Announces Enrollment of Next Two Patients in Phase I/II GlobeNewswire Inc

Sep 30, 2020

07:05AM EDT uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire Inc

Sep 25, 2020

07:11AM EDT uniQure Announces Data Safety Monitoring Board Review Of Phase I/II Clinical Trial Of AMT-130 Says 'No significant safety concerns were noted to prevent further dosing, and the next two patients are now cleared for enrollment in the study' Benzinga

07:09AM EDT UniQure Announces Recommendations From DSMB Of Phase I/II Clinical Trial Of AMT-130 For Huntington's Disease RTTNews

07:05AM EDT uniQure Announces Recommendations from Data Safety Monitoring GlobeNewswire Inc

Sep 3, 2020

07:05AM EDT uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire Inc

Aug 26, 2020

07:36AM EDT UniQure Appoints Ricardo Dolmetsch As President, Research & Development RTTNews

07:05AM EDT uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as GlobeNewswire Inc

Aug 25, 2020

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga

06:34AM EDT Raymond James Initiates Coverage On uniQure with Strong Buy Rating, Announces Price Target of $75 Benzinga

Aug 19, 2020

10:51AM EDT UniQure Shares Quiet; Cowen Says Spoke With Company, FDA Has Not Signaled Need For 2-Year ABR Data From Ongoing Pivotal Study Of EtranaDez In Hemophilia B Benzinga

Jul 31, 2020

09:36AM EDT Benzinga's Top Upgrades, Downgrades For July 31, 2020 Benzinga

06:00AM EDT Baird Upgrades uniQure to Outperform, Lowers Price Target to $57 Benzinga

Jul 30, 2020

08:35AM EDT uniQure Q2 EPS $(0.96) Down From $(0.83) YoY Benzinga

07:05AM EDT ~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQures Gene Therapy Candidate for Hemophilia B ~ GlobeNewswire Inc

document.getElementById("pj0NdY").onerror = function(){this.style.display='none';}; .dark-mode .B2sM0G{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .B2sM0G{ color: #333333; background-color: white; border: 2px solid #333333; }QUREuniQure N.V.stock NASDAQ

QURE
uniQure N.V.
stock NASDAQ